AEI panel examines medical malpractice

The American Enterprise Institute (AEI) held a panel discussion earlier this month, discussing medical malpractice reform along with a variety of other topics.

“The traditional political and policy battles over medical malpractice reform usually follow well-rehearsed scripts highlighting the relationships among the risk of lawsuits, defensive medicine and physician supply responses, and damage cap remedies,” the event description read. “Join AEI for a forum examining more recent research that suggests several empirical cracks in this storyline. Our panel will analyze fresh evidence on the direction and magnitude of medical liability’s causes and effects and then explore policy implications.”

AEI fellow Thomas P. Miller moderated the panel. The participants were:

  • Michael Morrisey, health economist, professor and chair of the department of health policy and management at the Texas A&M University School of Public Health
  • Anupam Jena, principal consultant at Precision Health Economics, assistant professor of health care policy and medicine at Harvard Medical School, and attending physician at Massachusetts General Hospital 
  • David Hyman, H. Ross and Helen Workman Chair in law and a professor of medicine at the University of Illinois

Click below to read a more extensive summary or watch the full discussion on AEI's website:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.